Is Kilitch Drugs overvalued or undervalued?

As of 17 November 2025, the valuation grade for Kilitch Drugs has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued based on its financial metrics, with a PE ratio of 22.78, an EV to EBITDA of 19.76, and a PEG ratio of 0.42. These ratios suggest that Kilitch Drugs is positioned competitively within its industry.
In comparison to its peers, Kilitch Drugs holds a PE ratio that is significantly lower than Sun Pharma's 36.69 and Divi's Lab's 69.78, both of which are categorized as expensive. Meanwhile, it is on par with Aurobindo Pharma, which has a PE of 21.23, and slightly below Cipla's 22.81, both of which are rated as fair or attractive. Notably, Kilitch Drugs has outperformed the Sensex over the longer term, with a 3-year return of 117.32% compared to the Sensex's 37.57%. This performance, coupled with its fair valuation, suggests that Kilitch Drugs is a solid investment opportunity in the current market landscape.